PrOKEDI® is now listed in Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia and Prince Edward Island, as well as through federal drug plans administered by the Non-Insured Health Benefits Program (NIHB), Veterans Affairs Canada (VAC), the Department of National Defence (DND) and Correctional Service Canada (CSC). 

PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults.1 PrOKEDI® is designed to provide rapid attainment of clinically relevant risperidone plasma concentrations, followed by sustained release over the four-week dosing interval, without the need for oral supplementation or a loading dose.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.